Joint comfort in motion

Joint comfort in motion

FWRD® is a mangosteen peel extract standardised in xanthones, designed to support healthy joint comfort and cartilage protection. Supported with a mechanistic study and a clinical trial. 200 mg/day. 

FWRD® - Key features

  • Mangosteen extract standardised in α + ɣ mangostins 
  • Fruit pericarp extract, a co-product of mangosteen juice manufacturing 
  • Complete characterisation of polyphenols & metabolites 
  • Clinically proven to promote healthy joint comfort 
  • Significant improvements in knee stiffness and functionality after 2 weeks 
  • Supports the modulation of cartilage degradation factors 

Science supporting FWRD®

FWRD® supports healthy joint comfort and cartilage protection. Its mechanism of action is supported by an ex vivo study demonstrating that FWRD® may prevent cartilage degradation and inflammation, which may be contributing to improved joint stiffness and enhanced joint function. Its clinical benefits are highlighted through a randomised, double-blind, multi-arm, parallel and placebo-controlled study, proving significant improvements in joint discomfort, knee stiffness and functionality.

Characterisation

FWRD® is a mangosteen peel extract standardised in xanthones. Sourced from Thailand or Malaysia, FWRD® is derived from the fruit pericarp, a co-product of the agro-industry, ensuring maximum raw material valorization.

Bioactive compounds

            Total Xanthones               37-48%
                   α + ɣ mangostins       29-41%

Composition: Mangosteen peel extract (Garcinia mangostana L.) - carrier-free

Recommended daily dosage: 200 mg

Mechanism of action

An ex vivo study conducted on blood collected from participants in the clinical trial confirms the mode of action of FWRD®, with a reduction of inflammation biomarkers, NO and PGE2, and catabolic biomarkers, MMP13 collagenase. 

FWRD® prevents inflammation. 

FWRD® reduces levels of NO and PGE2, markers of cartilage inflammation, indicating prevention of inflammatory processes.   

Fwrd inflammatory progression

FWRD® prevents cartilage degradation.

FWRD® prevents the increase of collagenase MMP13, a catabolic marker, suggesting protection against cartilage degradation.   

Fwrd cartilage degradation

By preventing cartilage degradation, FWRD® may be contributing to improved joint stiffness and enhanced function.

Clinically supported benefits

Randomised, double-blind, multi-arm, parallel and placebo-controlled study. 

LOCATION

Murcia, Spain
UCAM, University of Murcia

YEAR & DURATION 2023
12 weeks of supplementation
POPULATION

25 subjects per arm
Age: 39-65 years old
BMI: 20 - 33.1 kg/m2

  • Declaring knee joint pain during and/or after activity/exercise
  • Joint knee pain rating at least 4 on a 10 VAS following activity/exercise
  • Diagnosed osteoarthritis grade I or II according to Kellgren-Lawrence classification
PROTOCOL

Outcomes
WOMAC questionnaire
Total score, pain, stiffness, physical function

INTAKES

CAPSULE
200 mg of FWRD® or placebo
1 intake per day at breakfast

FWRD® has been demonstrated to significantly reduce joint discomfort from 28 days of supplementation, with notable improvements in knee stiffness and functionality.


fwrd joint discomfortSignificant improvement after 28 days on the total score for the supplemented group:  joint discomfort is reduced by 46% after 28 days vs baseline.

 

Stiffness and functional subscales reflect how daily activities are impacted by disability. 

fwrd stiffness functionalityAfter 16 days of supplementation:

  • Joint stiffness is reduced by 46% vs baseline.
  • Joint functionality is improved by 37% vs baseline.

FWRD® is ideal for integration into capsules, tablets, and sachets, empowering brands to deliver targeted support for active lifestyles and healthy ageing.

FWRD® is safe

No adverse event linked to FWRD® supplementation has been recorded.
12-week FWRD® supplementation does not affect biological & physiological safety parameters.

Regulatory & Certifications

Non-GMO, Halal, gluten-free, suitable for vegetarians.

New Dietary Ingredient (NDI) - NDIN accepted by FDA 

References

CLINICAL TRIALS
Romain C. & Cases J.; Agro Food Industry Hi Tech; 2015, 26(3):8-13
New study publication pending

This website is intended to provide information about Fytexia’s ingredients, used in various food/dietary supplement products around the world. It is only intended for business to business and to provide information to food/dietary supplement professionals and is not designed for the general public. Statements used on this website have not been evaluated by the Food and Drug Administration or any other competent authority. Products are not intended to diagnose, treat, cure or prevent any disease.